CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTET2MutationPrognosticSupportsBetter OutcomeMyelodysplastic SyndromeKosmider et al., 2009
BVHLMutationPrognosticSupportsBetter OutcomeClear Cell Renal Cell CarcinomaPatard et al., 2008
BTET2MutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGaidzik et al., 2012
BTET2MutationPrognosticSupportsAcute Myeloid LeukemiaMetzeler et al., 2011
BBCL2OverexpressionPrognosticSupportsPoor OutcomeDiffuse Large B-cell LymphomaGascoyne et al., 1997
BTET2MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaChou et al., 2011
BTET2MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMetzeler et al., 2011
BRUNX1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2011
BRUNX1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2011
BEWSR1::FLI1e7::e6PrognosticSupportsBetter OutcomeEwing Sarcomade Alava et al., 1998
BEZH2Y646DiagnosticSupportsPositiveDiffuse Large B-cell LymphomaMorin et al., 2010
BEZH2Y646DiagnosticSupportsPositiveFollicular LymphomaMorin et al., 2010
BBTKC481SPredictiveSupportsResistanceChronic Lymphocytic LeukemiaIbrutinibWoyach et al., 2014
DAKT1Q79KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DEML4::ALKFusion AND ALK G1202RPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2012
DEML4::ALKFusion AND ALK L1196MPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2012
DEML4::ALKFusion AND ALK S1206YPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2012
CEML4::ALKFusion AND ALK T1151dupPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2012
DAPCMutationPredictiveSupportsSensitivity/ResponseColorectal CancerG007-LKLau et al., 2013
DARF877LPredictiveSupportsResistanceProstate CancerApalutamide,EnzalutamideJoseph et al., 2013
DARW742PredictiveSupportsResistanceProstate CarcinomaBicalutamideHara et al., 2003
BASXL1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaShivarov et al., 2015
BAKAP9::BRAFFusionDiagnosticSupportsPositivePapillary Thyroid CarcinomaCiampi et al., 2005
BCCNE1AmplificationPrognosticSupportsPoor OutcomeOvarian CarcinomaNakayama et al., 2010
BCEBPAMutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaHo et al., 2009
BCEBPAMutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaMatsuo et al., 2014
BDNMT3AMutationPrognosticSupportsPoor OutcomeT-cell Acute Lymphoblastic LeukemiaGrossmann et al., 2013
BEGFRCopy Number VariationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaTemam et al., 2007
BEGFRAmplificationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaChung et al., 2006
BFOXL2C134WDiagnosticSupportsPositiveGranulosa Cell TumorJamieson et al., 2010
BIKZF1DeletionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaKrentz et al., 2013
BKITM541LDiagnosticDoes Not SupportPositiveChronic Myeloid LeukemiaKrüger et al., 2006
BKRASG12PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASG13PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASQ61PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BMGMTPromoter MethylationPrognosticSupportsBetter OutcomeOligodendrogliomavan den Bent et al., 2009
BNRASMutationPrognosticSupportsMultiple MyelomaChng et al., 2008
BPGRExpressionPredictiveDoes Not SupportSensitivity/ResponseBreast CancerExemestane,TamoxifenBartlett et al., 2011
BPGRExpressionPrognosticSupportsPoor OutcomeBreast CancerBartlett et al., 2011
BPTENDeletionPrognosticSupportsPoor OutcomeProstate AdenocarcinomaYoshimoto et al., 2007
DPTENLossPredictiveSupportsSensitivity/ResponseProstate CancerTemsirolimusNeshat et al., 2001
BRUNX1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMendler et al., 2012
BSF3B1MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaWan et al., 2013
BSMARCA4INACTIVATING MUTATIONPrognosticSupportsPoor OutcomeLung AdenocarcinomaJelinic et al., 2014
BTERTPromoter MutationPrognosticSupportsPoor OutcomeGlioblastomaNonoguchi et al., 2013
BTP53MutationPrognosticSupportsPoor OutcomeEsophagus Squamous Cell CarcinomaYamasaki et al., 2010
BTP53MutationPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaKrentz et al., 2013
BTP53MutationPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeBally et al., 2014
BTP53MutationPrognosticSupportsPoor OutcomeMyeloid NeoplasmChng et al., 2007
BTP53MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaAlsner et al., 2001
Page 7 of 96
PreviousNext